ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2874

Biological Roles of C5orf30 In Rheumatoid Arthritis Synovial Fibroblasts

Munitta Muthana1, Holly Davies2, Sachin Khetan3, Gbadebo Adeleke Adeleke4, Sarah Hawtree1 and Anthony G. Wilson5, 1Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 2University of Sheffield, Sheffield, United Kingdom, 3Infection and immunity, Dr, Sheffield, United Kingdom, 4Infection and Immunity, Dr, Sheffield, United Kingdom, 5Infection & Immunity, University of Sheffield, Sheffield, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Fibroblasts, Gene Expression, rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Pathogenetic Pathways

Session Type: Abstract Submissions (ACR)

Background/Purpose:

A recent genome wide association study identified the variant rs26232 in the first intron of an uncharacterized gene C5orf30 as a rheumatoid arthritis susceptibility variant. In addition, it has been associated with severity of radiological joint damage suggesting a role in tissue breakdown1. To date there is no function assigned for C5orf30 and neither the gene or protein show homology to any known functional sequences. However, C5orf30 is highly conserved in chimpanzee, dog, cow, mouse, chicken, and zebrafish (orthologs). The aim of this study is to determine the biological role of C5orf30 in rheumatoid arthritis synovial fibroblast.

Methods: Immunohistochemistry on synovial samples was used to determine expression of C5orf30 including co-localisation using antibodies to macrophages (CD68), fibroblasts (5B5), T (CD3) & B (CD19) cells. Real time PCR and western blotting were used to examine C5orf30 transcript and protein levels in fibroblast-like synovial cells (FLS stimulated with TNF & hypoxia). To investigate gene function siRNA was used to knockdown either C5orf30 or a non-targeting control (NTC) in synovial FLS in vitro.

Results:

Confocal microscopy revealed C5orf30 to be strongly expressed in both the nuclear and cytoplasmic compartment of synovial lining cells including macrophages and fibroblasts, but not T & B cells. C5orf30 was undetectable in arthroscopy sections obtained from osteoarthritis or control synovium. C5orf30 was expressed in FLS and was found to be up-regulated by hypoxia (8-fold) and down-regulated by TNF (0.5-fold). We found that C5orf30KD compared to the NTC increased the number of invading FLS using the Matrigel invasion assay (p=0.01) and increased FLS migration using a scratch assay (p=0.02) (n=6). Preliminary gene profiling studies suggest that multiple gene sets involved in cell proliferation, intracellular signal transduction, angiogenesis, and immune and inflammatory pathways were significantly modified following C5orf30KD.

Conclusion:

C5orf30 knockdown increased FLS migration and invasion into matrigel suggesting C5orf30 is negatively regulating cellular invasion. Together this identifies a potentially novel pathway mediating tissue damage in RA. We are currently performing proteomic and gene profiling (after C5orf30 KD) studies in order to work out the biology of this important marker in the pathogenesis and severity of RA.

1Teare, M.D., et al (in press). Allele dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis, Arthritis and Rheumatism.


Disclosure:

M. Muthana,
None;

H. Davies,
None;

S. Khetan,
None;

G. A. Adeleke,
None;

S. Hawtree,
None;

A. G. Wilson,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/biological-roles-of-c5orf30-in-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology